Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 313,935
  • Shares Outstanding, K 84,165
  • Annual Sales, $ 0 K
  • Annual Income, $ -135,960 K
  • 60-Month Beta 0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56
Trade AVIR with:

Options Overview Details

View History
  • Implied Volatility 315.72% ( +140.67%)
  • Historical Volatility 36.16%
  • IV Percentile 99%
  • IV Rank 75.56%
  • IV High 410.05% on 10/20/23
  • IV Low 24.08% on 10/16/23
  • Put/Call Vol Ratio 0.56
  • Today's Volume 81
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 4.05
  • Today's Open Interest 19,484
  • Open Int (30-Day) 21,039

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.61
  • Number of Estimates 3
  • High Estimate -0.57
  • Low Estimate -0.63
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -41.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.66 +1.09%
on 04/22/24
4.09 -9.54%
on 03/28/24
-0.36 (-8.87%)
since 03/22/24
3-Month
3.58 +3.50%
on 01/25/24
4.60 -19.57%
on 02/29/24
+0.10 (+2.78%)
since 01/24/24
52-Week
2.77 +33.82%
on 11/22/23
5.19 -28.71%
on 05/22/23
+0.49 (+15.26%)
since 04/24/23

Most Recent Stories

More News
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the Upgrade

Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVIR : 3.70 (-0.80%)
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)

The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...

AVIR : 3.70 (-0.80%)
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus

Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.

AMRN : 0.8786 (-0.53%)
AVIR : 3.70 (-0.80%)
AKRO : 20.26 (-3.52%)
IMVT : 28.80 (+0.66%)
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.

AMRN : 0.8786 (-0.53%)
AVIR : 3.70 (-0.80%)
DCPH : 14.62 (-0.34%)
AKRO : 20.26 (-3.52%)
Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings Season

Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

AVIR : 3.70 (-0.80%)
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

AMRN : 0.8786 (-0.53%)
EDIT : 5.35 (-2.01%)
AVIR : 3.70 (-0.80%)
AKRO : 20.26 (-3.52%)
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss

Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.

AMRN : 0.8786 (-0.53%)
ACAD : 16.59 (-0.90%)
AVIR : 3.70 (-0.80%)
AKRO : 20.26 (-3.52%)
Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.

HZNP : 116.30 (+0.04%)
AMRN : 0.8786 (-0.53%)
AVIR : 3.70 (-0.80%)
AKRO : 20.26 (-3.52%)
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.

ALKS : 24.65 (+1.61%)
AVIR : 3.70 (-0.80%)
RCUS : 15.43 (-0.45%)
AKRO : 20.26 (-3.52%)
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates

Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

NVO : 126.16 (-1.93%)
AVIR : 3.70 (-0.80%)
RCUS : 15.43 (-0.45%)
AKRO : 20.26 (-3.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 3.78
2nd Resistance Point 3.76
1st Resistance Point 3.73
Last Price 3.70
1st Support Level 3.68
2nd Support Level 3.65
3rd Support Level 3.62

See More

52-Week High 5.19
Fibonacci 61.8% 4.26
Fibonacci 50% 3.98
Last Price 3.70
Fibonacci 38.2% 3.69
52-Week Low 2.77

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar